InsidersTradesSigma
Follow the Prenetics Global Ltd stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €297.3m. The latest transaction was disclosed on 7 July 2026 (Levée d'options). Among the most active insiders: Leogrande Hudson Blake. All data is free.
Analysts rate Prenetics Global Ltd Strong Buy (bullish), based on 5 analysts. Average price target: US$31.00.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Prenetics Global Ltd is a company focused on genetic testing and digital health solutions. It operates on the XNAS stock market.